M
mrsam
Guest
The anti-cholesterol drug Praluent (alirocumab), made by France’s Sanofi Pharmaceuticals, is linked to a 15 percent lower risk of major cardiovascular events like heart attack and stroke, a study said Saturday. Alirocumab was also associated with a 15 percent reduction in death from any cause, marking the first …
Read more via Punch Newspapers – http://ift.tt/2FEaLoC
Get More Nigeria Metro News
Read more via Punch Newspapers – http://ift.tt/2FEaLoC
Get More Nigeria Metro News
Last edited by a moderator: